In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
Staphylococcus lugdunensis is an atypically virulent coagulase-negative staphylococcal species associated with acute and destructive infections that often resemble Staphylococcus aureus infections. Several types of infection caused by S. lugdunensis (e.g., native valve endocarditis, prosthetic joint infection, and intravascular catheter infection) are associated with biofilm formation, which may lead to an inability to eradicate the infection due to the intrinsic nature of biofilms to resist high levels of antibiotics. In this study, planktonic MICs and MBCs and biofilm bactericidal concentrations of 10 antistaphylococcal antimicrobial agents were measured for 15 S. lugdunensis isolates collected from patients with endocarditis, medical device infections, or skin and soft tissue infections. Planktonic isolates were susceptible to all agents studied, but biofilms were resistant to high concentrations of most of the drugs. However, moxifloxacin was able to kill 73% of isolates growing in biofilms at </=0.5 mug/ml. Relative to the effect on cell density, subinhibitory concentrations of nafcillin substantially stimulated biofilm formation of most isolates, whereas tetracycline and linezolid significantly decreased biofilm formation in 93 and 80% of isolates, respectively. An unexpected outcome of MBC testing was the observation that vancomycin was not bactericidal against 93% of S. lugdunensis isolates, suggesting widespread vancomycin tolerance in this species. These data provide insights into the response of S. lugdunensis isolates when challenged with various levels of antimicrobial agents in clinical use.
Frank
Kristi L
KL
Division of Infectious Diseases, Department of Medicine, Mayo Clinic College of Medicine, 200 First Street S.W., Rochester, MN 55905, USA.
Reichert
Emily J
EJ
Piper
Kerryl E
KE
Patel
Robin
R
D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000378:metabolism; D018441:Biofilms / Q000187:drug effects*; D004269:DNA, Bacterial / Q000235:genetics / Q000378:metabolism; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D009254:Nafcillin / Q000494:pharmacology; D023303:Oxazolidinones / Q000494:pharmacology; D046915:Penicillin-Binding Proteins; D010406:Penicillins / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013203:Staphylococcal Infections / Q000382:microbiology*; D013210:Staphylococcus / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology; D013752:Tetracycline / Q000494:pharmacology; D001618:beta-Lactamases / Q000378:metabolism
D000081:Acetamides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D023303:Oxazolidinones; D046915:Penicillin-Binding Proteins; D010406:Penicillins; C487789:mecA protein, Staphylococcus aureus; D009254:Nafcillin; D001618:beta-Lactamases; D013752:Tetracycline; D000069349:Linezolid